Uni Eropa - Italia - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. (miol) - ranolazina - angina pectoris - terapia cardiaca - ranexa è indicato come terapia aggiuntiva per il trattamento sintomatico di pazienti con angina pectoris stabile che non sono adeguatamente controllati o intolleranti alle terapie antianginose di prima linea (come beta-bloccanti e / o calcio-antagonisti).

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

boehringer ingelheim (schweiz) gmbh - tamsulosinum - retardtablette - tamsulosini hydrochloridum 400 µg corresp. tamsulosinum 367 µg, macrogolum 8000, magnesii stearas, macrogolum 7'000'000 cum e 321 et silica colloidalis hydrica, Überzug: hypromellosum, macrogolum 8000, e 172 (flavum), pro compresso obducto. - iperplasia prostatica benigna - synthetika

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

astellas pharma ag - tamsulosinum - retardtabletten - tamsulosini hydrochloridum 400 µg corresp. tamsulosinum 367 µg, macrogolum 8000, magnesii stearas, macrogolum 7'000'000 cum e 321 et silica colloidalis hydrica, Überzug: hypromellosum, macrogolum 8000, e 172 (flavum), pro compresso obducto. - iperplasia prostatica benigna - synthetika

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

axapharm ag - tamsulosini hydrochloridum - retardkapseln - tamsulosini hydrochloridum 0,4 mg, colore.: e 132, excipiens pro capsula. - iperplasia prostatica benigna - synthetika

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - tamsulosini hydrochloridum - depocaps - tamsulosini hydrochloridum 0,4 mg, colore.: e 132, excipiens pro capsula. - iperplasia prostatica benigna - synthetika

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - tamsulosini hydrochloridum - depocaps - tamsulosini hydrochloridum 0,4 mg, colore.: e 132, excipiens pro capsula. - iperplasia prostatica benigna - synthetika

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - tamsulosinum - retardkapseln - tamsulosini hydrochloridum 0,4 mg corrisp. tamsulosinum 0.367 mg, cellulosum microcristallinum, acidi methacrylici e ethylis acrylatis polymerisati 1:1 dispersio 30 per cento con polysorbatum 80 e natrii laurilsulfas corrisp. sodio 7.28 µg, triethylis citras, talco, kapselhülle: gelatina, e 132, e 171, e 172 (rosso) e 172 (giallo) e 172 (nero) per la capsula. - iperplasia prostatica benigna - synthetika

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - tamsulosinum - retardtabletten - tamsulosini hydrochloridum 0.4 mg corresp. tamsulosinum 0.367 mg, hypromellosum, cellulosum microcristallinum, carbomerum, silica colloidalis anhydrica, magnesii stearas, e 172 (rubrum), pro compresso obducto. - iperplasia prostatica benigna - synthetika

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - tamsulosinum - retardkapseln - tamsulosini hydrochloridum 0.4 mg corresp. tamsulosinum 0.367 mg, cellulosum microcristallinum, acidi methacrylici et ethylis acrylatis polymerisati 1:1 dispersio 30 per centum cum polysorbatum 80 et natrii laurilsulfas corresp. natrium 30 µg, triethylis citras, talcum, kapselhülle: gelatina, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), e 132 pro capsula. - iperplasia prostatica benigna - synthetika

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - tamsulosinum - retardtabletten - tamsulosini hydrochloridum 0.4 mg corresp. tamsulosinum 0.376 mg, hypromellosum, cellulosum microcristallinum, carbomerum, silica colloidalis anhydrica, magnesii stearas, e 172 (rubrum), pro compresso. - iperplasia prostatica benigna - synthetika